Deoxycholic acid-modified polyethylenimine based nanocarriers for RAGE siRNA therapy in acute myocardial infarction

Sook Hee Ku, Jueun Hong, Hyung Ho Moon, Ji Hoon Jeong, Hyejung Mok, Sungha Park, Donghoon Choi, Sun Hwa Kim

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The activation of receptor for advanced glycation end products (RAGE) signaling is mainly associated with myocardial ischemia/reperfusion injury. Thus the blockade of RAGE-ligands axis can be considered as a potential therapeutic strategy to protect myocardial infarction after ischemia/reperfusion injury. Herein, we strengthened the cardioprotective effect with combinatorial treatment of soluble RAGE (sRAGE) and RAGE siRNA (siRAGE) causing more effective suppression of RAGE-mediated signaling transduction. For pharmacological blockade of RAGE, sRAGE, the extracellular ligand binding domain of RAGE, acts as a pharmacological ligand decoy and inhibits the interaction between RAGE and its ligands. For genetic deletion of RAGE, siRAGE suppresses the expression of RAGE by participating in RNA interference mechanism. Therefore, we combined these two RAGE blockade/deletion strategies and investigated the therapeutic effects on rat ischemic and reperfused myocardium. According to our results, based on RAGE expression level analysis and infarct size/fibrosis measurement, co-treatment of sRAGE and siRAGE exhibited synergic cardioprotective effects; thus the newly designed regimen can be considered as a promising candidate for the treatment of myocardial infarction.

Original languageEnglish
Pages (from-to)1317-1324
Number of pages8
JournalArchives of pharmacal research
Volume38
Issue number7
DOIs
Publication statusPublished - 2015 Jul 25

Fingerprint

Polyethyleneimine
Deoxycholic Acid
Small Interfering RNA
Myocardial Infarction
Therapeutics
Ligands
Reperfusion Injury
Advanced Glycosylation End Product-Specific Receptor
Pharmacology
Myocardial Reperfusion Injury
Therapeutic Uses
RNA Interference
Myocardial Ischemia
Rats
Myocardium
Fibrosis

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Drug Discovery
  • Organic Chemistry

Cite this

Ku, Sook Hee ; Hong, Jueun ; Moon, Hyung Ho ; Jeong, Ji Hoon ; Mok, Hyejung ; Park, Sungha ; Choi, Donghoon ; Kim, Sun Hwa. / Deoxycholic acid-modified polyethylenimine based nanocarriers for RAGE siRNA therapy in acute myocardial infarction. In: Archives of pharmacal research. 2015 ; Vol. 38, No. 7. pp. 1317-1324.
@article{d80836d9179a4377a7fd248f1e512d68,
title = "Deoxycholic acid-modified polyethylenimine based nanocarriers for RAGE siRNA therapy in acute myocardial infarction",
abstract = "The activation of receptor for advanced glycation end products (RAGE) signaling is mainly associated with myocardial ischemia/reperfusion injury. Thus the blockade of RAGE-ligands axis can be considered as a potential therapeutic strategy to protect myocardial infarction after ischemia/reperfusion injury. Herein, we strengthened the cardioprotective effect with combinatorial treatment of soluble RAGE (sRAGE) and RAGE siRNA (siRAGE) causing more effective suppression of RAGE-mediated signaling transduction. For pharmacological blockade of RAGE, sRAGE, the extracellular ligand binding domain of RAGE, acts as a pharmacological ligand decoy and inhibits the interaction between RAGE and its ligands. For genetic deletion of RAGE, siRAGE suppresses the expression of RAGE by participating in RNA interference mechanism. Therefore, we combined these two RAGE blockade/deletion strategies and investigated the therapeutic effects on rat ischemic and reperfused myocardium. According to our results, based on RAGE expression level analysis and infarct size/fibrosis measurement, co-treatment of sRAGE and siRAGE exhibited synergic cardioprotective effects; thus the newly designed regimen can be considered as a promising candidate for the treatment of myocardial infarction.",
author = "Ku, {Sook Hee} and Jueun Hong and Moon, {Hyung Ho} and Jeong, {Ji Hoon} and Hyejung Mok and Sungha Park and Donghoon Choi and Kim, {Sun Hwa}",
year = "2015",
month = "7",
day = "25",
doi = "10.1007/s12272-014-0527-x",
language = "English",
volume = "38",
pages = "1317--1324",
journal = "Archives of Pharmacal Research",
issn = "0253-6269",
publisher = "Pharmaceutical Society of Korea",
number = "7",

}

Deoxycholic acid-modified polyethylenimine based nanocarriers for RAGE siRNA therapy in acute myocardial infarction. / Ku, Sook Hee; Hong, Jueun; Moon, Hyung Ho; Jeong, Ji Hoon; Mok, Hyejung; Park, Sungha; Choi, Donghoon; Kim, Sun Hwa.

In: Archives of pharmacal research, Vol. 38, No. 7, 25.07.2015, p. 1317-1324.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Deoxycholic acid-modified polyethylenimine based nanocarriers for RAGE siRNA therapy in acute myocardial infarction

AU - Ku, Sook Hee

AU - Hong, Jueun

AU - Moon, Hyung Ho

AU - Jeong, Ji Hoon

AU - Mok, Hyejung

AU - Park, Sungha

AU - Choi, Donghoon

AU - Kim, Sun Hwa

PY - 2015/7/25

Y1 - 2015/7/25

N2 - The activation of receptor for advanced glycation end products (RAGE) signaling is mainly associated with myocardial ischemia/reperfusion injury. Thus the blockade of RAGE-ligands axis can be considered as a potential therapeutic strategy to protect myocardial infarction after ischemia/reperfusion injury. Herein, we strengthened the cardioprotective effect with combinatorial treatment of soluble RAGE (sRAGE) and RAGE siRNA (siRAGE) causing more effective suppression of RAGE-mediated signaling transduction. For pharmacological blockade of RAGE, sRAGE, the extracellular ligand binding domain of RAGE, acts as a pharmacological ligand decoy and inhibits the interaction between RAGE and its ligands. For genetic deletion of RAGE, siRAGE suppresses the expression of RAGE by participating in RNA interference mechanism. Therefore, we combined these two RAGE blockade/deletion strategies and investigated the therapeutic effects on rat ischemic and reperfused myocardium. According to our results, based on RAGE expression level analysis and infarct size/fibrosis measurement, co-treatment of sRAGE and siRAGE exhibited synergic cardioprotective effects; thus the newly designed regimen can be considered as a promising candidate for the treatment of myocardial infarction.

AB - The activation of receptor for advanced glycation end products (RAGE) signaling is mainly associated with myocardial ischemia/reperfusion injury. Thus the blockade of RAGE-ligands axis can be considered as a potential therapeutic strategy to protect myocardial infarction after ischemia/reperfusion injury. Herein, we strengthened the cardioprotective effect with combinatorial treatment of soluble RAGE (sRAGE) and RAGE siRNA (siRAGE) causing more effective suppression of RAGE-mediated signaling transduction. For pharmacological blockade of RAGE, sRAGE, the extracellular ligand binding domain of RAGE, acts as a pharmacological ligand decoy and inhibits the interaction between RAGE and its ligands. For genetic deletion of RAGE, siRAGE suppresses the expression of RAGE by participating in RNA interference mechanism. Therefore, we combined these two RAGE blockade/deletion strategies and investigated the therapeutic effects on rat ischemic and reperfused myocardium. According to our results, based on RAGE expression level analysis and infarct size/fibrosis measurement, co-treatment of sRAGE and siRAGE exhibited synergic cardioprotective effects; thus the newly designed regimen can be considered as a promising candidate for the treatment of myocardial infarction.

UR - http://www.scopus.com/inward/record.url?scp=84937735945&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937735945&partnerID=8YFLogxK

U2 - 10.1007/s12272-014-0527-x

DO - 10.1007/s12272-014-0527-x

M3 - Article

C2 - 25559468

AN - SCOPUS:84937735945

VL - 38

SP - 1317

EP - 1324

JO - Archives of Pharmacal Research

JF - Archives of Pharmacal Research

SN - 0253-6269

IS - 7

ER -